Penzberg, Germany, January 31, 2012 / B3C newswire / - As of February 1, 2012, Dan Zabrowski is Head of Roche Applied Science in the Diagnostics Division, located in Penzberg, Germany. He succeeds Paul Brown who has led Roche Applied Science since September 2011. Dan Zabrowski will report to Daniel O’Day, COO Roche Diagnostics.
Dan recently served as Global Head of Roche Partnering and was a member of the Roche Corporate Executive Committee and Chugai Board. He joined Roche in 1994 through the acquisition of Syntex. During his career at Roche, Dan held a number of management positions in Regulatory Affairs and Development. Dan holds a Ph.D. in Organic Chemistry from the University of Indiana.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80’000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
All trademarks used or mentioned in this release are protected by law.
For further information please contact:
Dr. Burkhard Ziebolz
Phone: +49 8856 604830